Fitusiran Alternatives Compared
| Fitusiran | Advate (antihemophilic factor) | Hemlibra (emicizumab) |
|
|---|
| Fitusiran | Advate (antihemophilic factor) | Hemlibra (emicizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hemophilia A with Inhibitors, Hemophilia A, Hemophilia B, Hemophilia B with Inhibitors. Fitusiran may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Hemophilia A. Advate may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Hemophilia A, Hemophilia A with Inhibitors. Hemlibra may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||||||||||
| More about Fitusiran | More about Advate (antihemophilic factor) | More about Hemlibra (emicizumab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Advate has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Hemlibra has an average rating of 10.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Fitusiran side effects |
View all Advate side effects |
View all Hemlibra side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Advate prices |
View all Hemlibra prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Qfitlia | Other antihemophilic factor brands include: Adynovate, Afstyla, Altuviiio, Beriate P, Bioclate, Biostate, Eloctate, Esperoct, Factane, Fanhdi, Genarc, Helixate FS, Hemofil-M, Hyate:C, Jivi, Koate, Koate-DVI, Kogenate FS, Kovaltry, Monoclate-P, NovoEight, Nuwiq, Obizur, Recombinate, Xyntha View more |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
7.98 hours |
24 hours |
667.2 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 44 drugs are known to interact with Fitusiran:
|
A total of 10 drugs are known to interact with Advate:
|
A total of 8 drugs are known to interact with Hemlibra:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
March 28, 2025 |
N/A |
November 16, 2017 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Qfitlia
Qfitlia is used for hemophilia a, hemophilia a with inhibitors, hemophilia b, hemophilia b with ...
Hemlibra
Hemlibra is a monoclonal antibody that functions in place of a natural blood-clotting factor that ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Alhemo
Alhemo is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in ...
Profilnine
Profilnine is used for factor ix deficiency, factor vii deficiency, hemophilia a with inhibitors ...
Concizumab
Concizumab is used for hemophilia a with inhibitors, hemophilia b with inhibitors
Emicizumab
Emicizumab is used for hemophilia a, hemophilia a with inhibitors
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.